LUXEMBOURG – In a significant move to fortify the resilience of Lebanon’s crumbling healthcare system, the World Health Organization (WHO) and the European Investment Bank (EIB Global) have formalized a landmark agreement. Signed on March 6, 2025, during the prestigious EIB Group Forum in Luxembourg, the initiative injects €10 million in grant funding aimed at the dual objectives of reconstructing critical national diagnostic capacity and securing essential life-saving medicines for the country’s most vulnerable populations.
The agreement, signed by WHO Director-General Dr. Tedros Adhanom Ghebreyesus and EIB Vice-President Thomas Östros, marks a pivot toward sustainable health development in a nation that has been grappling with years of political instability, economic collapse, and the ongoing pressures of regional conflict.
The Core Mandate: Restoring National Diagnostics and Essential Care
The €10 million infusion is not merely a stop-gap measure; it is designed to address the foundational weaknesses that have plagued the Lebanese public health sector since the onset of the 2019 financial crisis.
Re-establishing the Central Public Health Laboratory (CPHL)
The centerpiece of this initiative is the restoration of Lebanon’s Central Public Health Laboratory. Once the bedrock of the country’s epidemiological surveillance and diagnostic testing capacity, the CPHL has suffered from years of neglect, lack of maintenance, and brain drain. By modernizing this facility, the WHO and EIB aim to restore Lebanon’s ability to conduct advanced disease surveillance, ensuring that the country can detect and respond to outbreaks—ranging from waterborne diseases to potential pandemic threats—with speed and scientific rigor.
Securing the Pharmaceutical Supply Chain
Beyond infrastructure, the grant directly targets the humanitarian crisis currently affecting Lebanese patients. For years, the country has faced chronic shortages of imported medicines, leaving those with non-communicable diseases (NCDs) in a precarious position. This initiative prioritizes the procurement and distribution of essential medications for more than 50,000 individuals suffering from diabetes, cardiovascular diseases, and various forms of cancer.
Chronology of Crisis and Intervention
To understand the weight of this €10 million agreement, one must contextualize the timeline of Lebanon’s health degradation.
- 2019–2020: The onset of the Lebanese liquidity crisis leads to the rapid devaluation of the national currency. Public hospitals begin to face severe budget cuts, and private medical importers struggle to secure foreign exchange, leading to the first major wave of medicine shortages.
- August 4, 2020: The Beirut Port explosion causes catastrophic damage to health infrastructure, destroying medical supplies and severely damaging hospitals in the capital, further stressing an already overwhelmed system.
- 2021–2023: Hyperinflation renders imported healthcare services unaffordable for the majority of the population. The "brain drain" accelerates as thousands of doctors and nurses emigrate.
- 2024: Regional tensions escalate, leading to further displacement of people and additional strain on the primary healthcare network.
- March 6, 2025: WHO and EIB Global sign the grant agreement in Luxembourg, signaling a shift from emergency response to structural reconstruction.
Supporting Data: The Scale of the Need
The data underpinning this collaboration highlights the urgency of the intervention. According to recent WHO assessments, the Lebanese healthcare system has been operating at a fraction of its pre-2019 capacity.
- The NCD Burden: Non-communicable diseases are the leading cause of death in Lebanon, accounting for over 90% of all mortality. The disruption in the supply of insulin, antihypertensives, and chemotherapy drugs has resulted in a surge of preventable complications and premature deaths.
- Public Laboratory Decline: The CPHL, which served as the primary diagnostic hub during the COVID-19 pandemic, faced critical failures in 2023 due to power outages and lack of reagents. The restoration of this laboratory is expected to reduce the national reliance on costly private diagnostic centers, which are often inaccessible to the low-income population.
- The Vulnerable Population: The initiative’s target of 50,000 patients represents a vital lifeline for those who have been forced to choose between food and medicine. With the poverty rate in Lebanon hovering above 80%, this targeted subsidy is essential for maintaining basic human security.
Official Responses and Strategic Rationale
Speaking at the EIB Group Forum, Dr. Tedros Adhanom Ghebreyesus emphasized that the partnership is a testament to the power of multilateral cooperation in health. "Public health is the bedrock of societal stability," Dr. Tedros noted. "By re-establishing the Central Public Health Laboratory, we are not just fixing a building; we are rebuilding the eyes and ears of the Lebanese health system. This is a critical investment in regional health security."
Thomas Östros, Vice-President of the European Investment Bank, reiterated the EIB’s commitment to the Mediterranean region. "The EIB is proud to partner with the WHO to address the urgent needs of the Lebanese people. Our mandate is to foster sustainable development, and there is no development without a functioning health sector. This €10 million grant is a strategic move to ensure that, despite the political and economic hardships, the most vulnerable citizens receive the life-saving treatment they deserve."
The European Union, which provides significant backing to the EIB, views this project as part of its broader strategy to support Lebanon’s transition toward stability. By focusing on essential medicine and public laboratory infrastructure, the EU is addressing the systemic fragility that could otherwise lead to a public health catastrophe.
Broader Implications: A Model for Resilient Recovery
The collaboration between the WHO and the EIB offers a potential blueprint for how international financial institutions and UN agencies can cooperate in "fragile settings."
From Humanitarian Aid to Development
Traditionally, the UN focuses on immediate humanitarian relief, while the EIB focuses on long-term infrastructure and development. This project bridges that gap. By using a grant to build "hard" infrastructure (the lab) alongside "soft" support (medicine provision), the two organizations are creating a sustainable recovery model.
Strengthening Regional Health Security
Lebanon’s health stability has regional implications. A collapse of the Lebanese health system could lead to uncontrolled disease transmission, placing pressure on neighboring countries. The revitalization of the CPHL ensures that Lebanon can once again contribute to regional health surveillance networks, providing data and insights that help keep the wider Eastern Mediterranean region safe.
The Challenge of Sustainability
Despite the success of this agreement, experts warn that long-term success depends on broader economic reforms within Lebanon. While the €10 million grant provides a vital buffer, the ultimate goal must be the restoration of a local pharmaceutical production capacity and a reliable, national electricity grid to power laboratories and hospitals.
The WHO and EIB have signaled that this is the beginning of a multi-phase engagement. Future efforts will likely look at solarizing health facilities and digitalizing health records, further reducing the reliance on unstable national utilities.
Conclusion
The agreement signed on March 6, 2025, is a significant milestone in the ongoing efforts to stabilize Lebanon. By tackling the root causes of diagnostic failure and medication scarcity, the WHO and EIB Global are providing more than just funds—they are providing hope to 50,000 families and a structural foundation for a nation struggling to reclaim its path to prosperity.
As the implementation phase begins, the eyes of the international community will be on the execution of these projects. The success of this initiative will serve as a bellwether for future international efforts to support nations in crisis, proving that even in the most challenging environments, strategic investment can secure the fundamental right to health.
For more information on this initiative and ongoing efforts, please contact the WHO Media Team or visit the official EIB Global website.
About the Author
